{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-002893","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2022-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.889422+00:00","generated_at":"2026-06-27T13:10:28.586736+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Indaptus Therapeutics enters employment agreement with CFO Nir Sassi; base salary $345,000","bullets":["Annual base salary of $345,000 with annual review; eligible for target bonus up to 40% of base salary.","Prior consulting agreement terminated; separately agreed to pay $195,728 termination payment to Mr. Sassi.","Severance of 12 months base salary if terminated without cause or resigns for good reason.","Change-in-control severance: 12 months base plus target bonus, plus accelerated equity vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-002893","json":"https://secwatch.observer/filing/0001493152-22-002893.json","markdown":"https://secwatch.observer/filing/0001493152-22-002893.md","text":"https://secwatch.observer/filing/0001493152-22-002893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222002893/0001493152-22-002893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222002893/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T13:10:28.586736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9a75f5509","claim":"Nir Sassi was appointed as Chief Financial Officer at Indaptus Therapeutics, Inc..","evidence_excerpt":"On February 1, 2022, Intec Pharma Ltd. (“Intec”), a wholly owned subsidiary of Indaptus Therapeutics, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Nir Sassi, the Company’s Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222002893/0001493152-22-002893-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}